The non-dilutive nature of the financing removes near-term equity issuance risk and supports aggressive share repurchases, which could accelerate EPS accretion. Traders should monitor pace of buybacks and upcoming regulatory milestones for Ziihera in mGEA, which could trigger additional payments.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $23.31entry
- T+1 · 9mo ago +4.89%α +5.81% · $24.45
- T+5 · 8mo ago +4.03%α +5.24% · $24.25
- T+20 · 8mo ago +3.86%α +11.80% · $24.21
- T+60 · 6mo ago +8.97%α −0.36% · $25.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks secured $250 million in non-dilutive financing from Royalty Pharma through a royalty-backed note, funded by 30% of future worldwide royalties on Ziihera sales. The deal extends Zymeworks' cash runway beyond 2028 and supports share repurchases and potential acquisitions, while the company retains 70% of royalties and all milestone payments.
Key Financial Metrics
Key Facts
- Zymeworks to receive $250 million from Royalty Pharma via a non-recourse, royalty-backed note
- Repayment sourced from 30% of global tiered royalties on Ziihera sales; Zymeworks retains 70%
- Royalty Pharma's cumulative repayment capped at 1.65x by 2033 or 1.925x thereafter (~$412.5M max)
- Proceeds to fund stock repurchases, potential acquisitions, and extend cash runway beyond 2028
- Zymeworks retains all milestone payments, including up to $1.5 billion in potential future payments
Financial Impact
$250 million in non-dilutive capital with no equity issuance; estimated maximum repayment of $481.25 million (1.925x $250M) over time from 30% of Ziihera royalties
Risk Factors
- Repayment obligations may constrain royalty income if Ziihera sales exceed expectations
- Ziihera's commercial success is not guaranteed; continued FDA approval depends on confirmatory trial results
- Failure to execute on acquisitions or repurchases efficiently could limit shareholder value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247161 |
Track record
25 reports on ZYME
5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers